- Home
- FGF vs ATHA Comparison
FGF vs ATHA Comparison
Compare FGF & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGF
- ATHA
- Stock Information
- Founded
- FGF 2012
- ATHA 2011
- Country
- FGF United States
- ATHA United States
- Employees
- FGF N/A
- ATHA N/A
- Industry
- FGF Property-Casualty Insurers
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- FGF Finance
- ATHA Health Care
- Exchange
- FGF Nasdaq
- ATHA Nasdaq
- Market Cap
- FGF 20.2M
- ATHA 21.0M
- IPO Year
- FGF N/A
- ATHA 2020
- Fundamental
- Price
- FGF $17.20
- ATHA $0.25
- Analyst Decision
- FGF
- ATHA Buy
- Analyst Count
- FGF 0
- ATHA 4
- Target Price
- FGF N/A
- ATHA $11.25
- AVG Volume (30 Days)
- FGF 1.2K
- ATHA 202.0K
- Earning Date
- FGF 05-19-2025
- ATHA 05-14-2025
- Dividend Yield
- FGF N/A
- ATHA N/A
- EPS Growth
- FGF N/A
- ATHA N/A
- EPS
- FGF N/A
- ATHA N/A
- Revenue
- FGF $17,348,000.00
- ATHA N/A
- Revenue This Year
- FGF N/A
- ATHA N/A
- Revenue Next Year
- FGF N/A
- ATHA N/A
- P/E Ratio
- FGF N/A
- ATHA N/A
- Revenue Growth
- FGF 1.49
- ATHA N/A
- 52 Week Low
- FGF $14.21
- ATHA $0.22
- 52 Week High
- FGF $38.40
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- FGF 53.40
- ATHA 43.26
- Support Level
- FGF $16.27
- ATHA $0.23
- Resistance Level
- FGF $17.27
- ATHA $0.31
- Average True Range (ATR)
- FGF 0.30
- ATHA 0.03
- MACD
- FGF 0.20
- ATHA 0.00
- Stochastic Oscillator
- FGF 96.05
- ATHA 30.00
About FGF FG Financial Group Inc. (NV)
Fundamental Global Inc through its subsidiaries operates as diversified insurance, reinsurance, and investment management holding company. The company's segments includes Insurance and Asset Management. It generates maximum revenue from the Insurance segment.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.